RxDoctor Payments Data

John Averette, MD

Gastroenterology · Tupelo, MSNPI 1366477390

Payments from drug & device makers

$1,661in general payments, 2019–2025

Across 83 payments — averaging $20.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$334
  • Phathom Pharmaceuticals, Inc.$325
  • Sanofi$153
  • Gilead$123
  • Pfizer$118
  • Intra-sana Laboratories$116
  • plus $493 from 11 others

What the payments were for

  • Food & beverage$1,56194%
  • Gifts$1006%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,661 in reported general payments places this provider in the 25th percentile of 127 gastroenterology providers in Mississippi.

See all gastroenterology providers in Mississippi

Medicare billing

Part B allowed, 2024
$238,460
Medicare patients
696
Services billed
5,688

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab19$533,458
LinzessLinaclotide55$49,154
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates203$13,100
Methscopolamine Bromide24$3,930
Dicyclomine Hcl198$3,305
Budesonide DrBudesonide26$2,904
Sucralfate14$2,313
SutabSod Sulf/Pot Chloride/Mag Sulf14$2,256
Pantoprazole Sodium248$2,189
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag15$1,789
CholestyramineCholestyramine (With Sugar)37$1,738
Famotidine91$1,093
Omeprazole99$1,088
Esomeprazole Magnesium41$967
Balsalazide Disodium11$482

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$108$533,45819 claims
AbbVieLinzess$334$49,15455 claims
Braintree Laboratories, Inc.Sutab, Suflave$17$4,04529 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 127 gastroenterology providers in Mississippi.

Other gastroenterology in Tupelo

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →